Important note: Information in this article was accurate in 2008. The state of the art may have changed since the publication date.
Bangkok Post - September 10, 2008
Apiradee Treerutkuarkul
The letter claimed the Public Health Ministry did not have the right to use CL to bypass the patent of its breast cancer drug Docetaxel.
The company cited articles 50 and 51 of the Patent Act, which stipulate that the Commerce Ministry had sole authority to announce the policy.
Also, the company could take legal action against the Government Pharmaceutical Organisation (GPO) if its copycat version from India was imported to Thailand without permission.
The Aids Access Foundation yesterday called on the Council of State to put public benefits above business.
The NGO also condemned the drug company for not respecting Thailand's rights under the World Trade Organisation's Agreement on Trade-Related Aspects of Intellectual Property Rights, which allows a government to use CL.
The group also lashed out at the Commerce Ministry for failing to protect public benefits through access to affordable life-saving drugs.
"Even the World Bank applauds the efficacy of the Thai policy on Aids drugs distribution," the group said in its statement released yesterday. "Without compulsory licensing the government cannot afford to buy expensive drugs for HIV-positive people. Therefore it is the responsibility of every state agency to consciously protect public benefits."
GPO board chairman Vichai Chokewiwat said he and officials from the National Health Security Office would testify to the Council of State today.
He insisted the policy was legitimate under article 51 (2) of the Patent Act, which allows governmental bodies to exercise a compulsory licensing policy. The GPO's legal department and an IP law expert agreed, he said.
"Such a request is nonsense," Dr Vichai said.
"The IP Department has the authority only to finalise the royalty fee which the government has to pay to the drug patent owner only."
Sanofi's Docetaxel is one of the four drugs named under the CL policy announced by former public health minister Mongkol Na Songkhla in January.
The others are the breast cancer drug Letrozole and the leukaemia and gastrointestinal stromal tumour drug Imatinib, both produced by Novartis; and lung cancer drug Erlotinib, made by Roche.
080910
BP080902
Copyright © 2008 - The Bangkok Post. Reproduction of this article (other than one copy for personal reference) must be cleared through the Bangkok Post.
AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Broadway Cares/Equity Fights AIDS, Elton John AIDS Foundation, the National Library of Medicine, Pacific Life Foundation and donations from users like you.
Always watch for outdated information. This article first appeared in 2008. This material is designed to support, not replace, the relationship that exists between you and your doctor.
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Copyright ©1980, 2008. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .